Antibody composition for detecting minimal residual lesions of multiple myeloma, kit and application

Abstract

The invention discloses an antibody composition for detecting multiple myeloma minimal residual diseases, a kit and application, and belongs to the technical field of blood tumor treatment effect monitoring. According to the novel flow antibody combination scheme capable of being used for MRD monitoring of myeloma patients disclosed by the invention, CD319 or CD269 and other seven antibodies (CD138 / CD38 / CD184 / CD27 / CD19 / CD56 / ckappa / clamda) are combined to form a fixed combination of two groups of antibodies; through verification of 303 cases of myeloma patients, the antibody combination is feasible, accurate, convenient and fast, can be used for MRD monitoring after conventional chemotherapeutic drug treatment, and provides a good solution for the problem that MRD monitoring is difficult after DARA treatment.

Description

technical field [0001] The invention belongs to the technical field of curative effect monitoring for hematological tumor treatment, and relates to a flow-type antibody combination scheme, in particular to an antibody composition, kit and application for detecting multiple myeloma minimal residual disease. Background technique [0002] Multiple myeloma is a hematologic malignancy that remains incurable despite the advent of novel targeted drugs that have greatly improved patient survival. The consensus of the current industry guidelines recommends that patients receive continuous treatment, and the endpoint of treatment depends on whether minimal residual disease (MRD) is negative. At present, the main means of monitoring MRD is the immunophenotyping technology of flow cytometry. By analyzing the bone marrow samples of patients, it is determined whether they are MRD-, especially for patients whose MRD- status lasts for more than 1 year after hematopoietic stem cell transplan...

AI Technical Summary

Problems solved by technology

However, the application of the recently marketed new antibody drug CD38 monoclonal antibody (DARA for short) targeting myeloma cells has brought difficulties to MRD monitoring, because after DARA treatment, the expression of CD38 antigen on the surface of bone marrow plasma cells in patients will be down-regulated or even converted to MRD. Negative (reports in the literature and previous studies of our research group have confirmed this phenomenon), at this time the currently recommended antibody combination cannot accurately circle plasma cells, resulting in false negatives in MRD detection

Therefore, there is an urgent need to develop new antibody combination regimens for accurate detection of patients treated with DARA to avoid false negative MRD, resulting in premature termination of treatment

[0003] At present, the DARA drug has just entered the clinic, and there is no unified recommendation for the flow cytometry antibody combination scheme for MRD monitoring of myeloma patients after treatment with the drug.

Images